TapewireFind a company

person · Reporting owner

Meisner Lara

Disclosed activity across 2 companies

Tapewire entity
67804
SEC CIK
0001883986

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Bicara Therapeutics Inc.BCAX · Entity 4673Chief Legal OfficerFebruary 02, 2026February 04, 2026
Viridian Therapeutics, Inc.\DEVRDN · Entity 4316Chief Legal OfficerJune 15, 2023June 20, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bicara Therapeutics Inc.

Report date February 02, 2026 · Filed February 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.76 · Expires 2036-02-02Direct90,000 Reported balance After 2026-02-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-02 · Grant · Acquired 90,000 · Balance 90,000

F1: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Viridian Therapeutics, Inc.\DE

Report date June 15, 2023 · Filed June 20, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect29,971 Ending reported balance After 2023-06-16 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2023-06-15 · Exercise / conversion · Acquired 2,269 · Balance 32,240

Row 2 · 2023-06-15 · Sale · Disposed 2,269 · Balance 29,971

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Row 3 · 2023-06-16 · Exercise / conversion · Acquired 27 · Balance 29,998

Row 4 · 2023-06-16 · Sale · Disposed 27 · Balance 29,971

F2: This transaction was executed pursuant to the Plan.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-18Direct37,481 Reported balance After 2023-06-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-06-15 · Exercise / conversion · Disposed 2,269 · Balance 37,481

F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-18Direct37,453 Reported balance After 2023-06-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-06-16 · Exercise / conversion · Disposed 28 · Balance 37,453

F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed pursuant to the Plan.

F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 02, 2026 Filed Feb 4, 2026 21:34 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 GrantStock Option (Right to Buy) · Derivative 90,000 $0.00 Strike: $16.76 $0.00
Disclosure

SEC source: 0001628280-26-005474 · wk-form4_1770240841.xml · derivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-02-02

F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
September 29, 2025 Filed Oct 1, 2025 20:57 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 33,807 $0.00 Strike: $9.24 $0.00
Disclosure

SEC source: 0001883986-25-000009 · wk-form4_1759352250.xml · derivative · entry 3

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,423

Underlying: Common Stock · 33,807 shares

Expires 2034-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F2 · derivative.exercise_date: 25% of the shares underlying this option vested on August 13, 2025, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
September 29, 2025 Filed Oct 1, 2025 20:57 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 SaleCommon Stock 33,807 $14.75 $498,653.25
Disclosure

SEC source: 0001883986-25-000009 · wk-form4_1759352250.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

Read SEC document
September 29, 2025 Filed Oct 1, 2025 20:57 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionCommon Stock 33,807 $9.24 $312,495.00
Disclosure

SEC source: 0001883986-25-000009 · wk-form4_1759352250.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,807

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 21:01 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 9,744 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · derivative · entry 4

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,699

Underlying: Common Stock · 9,744 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F4 · derivative.exercise_date: 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 21:01 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 6,085 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · derivative · entry 3

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,769

Underlying: Common Stock · 6,085 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 21:01 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 SaleCommon Stock 15,829 $11.49 $181,875.21
Disclosure

SEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.34 to $11.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 21:01 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionCommon Stock 15,829 $5.45 $86,268.05
Disclosure

SEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

Read SEC document
June 16, 2025 Filed Jun 18, 2025 21:12 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 9,744 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · derivative · entry 4

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,443

Underlying: Common Stock · 9,744 shares

Expires 2033-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F4 · derivative.exercise_date: 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
June 16, 2025 Filed Jun 18, 2025 21:12 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 6,085 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · derivative · entry 3

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,854

Underlying: Common Stock · 6,085 shares

Expires 2033-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
June 16, 2025 Filed Jun 18, 2025 21:12 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 SaleCommon Stock 15,829 $10.43 $165,096.47
Disclosure

SEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Read SEC document
June 16, 2025 Filed Jun 18, 2025 21:12 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionCommon Stock 15,829 $5.45 $86,268.05
Disclosure

SEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 22:35 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 30,246 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0000950170-25-041546 · ownership.xml · derivative · entry 5

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,119

Underlying: Common Stock · 30,246 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 22:35 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionStock Option (Right to Buy) · Derivative 48,720 $0.00 Strike: $5.45 $0.00
Disclosure

SEC source: 0000950170-25-041546 · ownership.xml · derivative · entry 4

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,187

Underlying: Common Stock · 48,720 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F4 · derivative.exercise_date: 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 22:35 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 SaleCommon Stock 30,620 $13.24 $405,512.91
Disclosure

SEC source: 0000950170-25-041546 · ownership.xml · nonDerivative · entry 3

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 22:35 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 SaleCommon Stock 48,526 $12.69 $615,697.89
Disclosure

SEC source: 0000950170-25-041546 · ownership.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,620

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.05 to $13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 22:35 UTC Bicara Therapeutics Inc. BCAX · Entity 4673 Exercise / conversionCommon Stock 79,146 $5.45 $431,345.70
Disclosure

SEC source: 0000950170-25-041546 · ownership.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,145

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024.

Read SEC document
June 16, 2023 Filed Jun 20, 2023 21:23 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 28 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-23-015998 · doc4.xml · derivative · entry 6

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,453

Underlying: Common Stock · 28 shares

Expires 2031-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
June 16, 2023 Filed Jun 20, 2023 21:23 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 27 $28.35 $765.45
Disclosure

SEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 4

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,971

F2 · kind: This transaction was executed pursuant to the Plan.

Read SEC document
June 16, 2023 Filed Jun 20, 2023 21:23 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 27 $23.03 $621.81
Disclosure

SEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 3

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,998

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 21:23 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 2,269 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-23-015998 · doc4.xml · derivative · entry 5

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,481

Underlying: Common Stock · 2,269 shares

Expires 2031-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 21:23 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 2,269 $28.02 $63,577.38
Disclosure

SEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,971

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 21:23 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 2,269 $23.03 $52,255.07
Disclosure

SEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 06, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 5,126 $0.00 Strike: $18.51 $0.00
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · derivative · entry 9

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,375

Underlying: Common Stock · 5,126 shares

Expires 2032-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
June 06, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 5,126 $25.02 $128,252.52
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 6

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,971

F3 · kind: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · price: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 06, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 5,126 $18.51 $94,882.26
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 5

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 05, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 499 $0.00 Strike: $18.51 $0.00
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · derivative · entry 8

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,501

Underlying: Common Stock · 499 shares

Expires 2032-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
June 05, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 499 $25.03 $12,489.97
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 4

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,971

F2 · kind: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · price: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 05, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 499 $18.51 $9,236.49
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 3

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,470

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 1,875 $0.00 Strike: $14.00 $0.00
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · derivative · entry 7

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,128

Underlying: Common Stock · 1,875 shares

Expires 2031-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 1,875 $24.21 $45,393.75
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,971

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 23:41 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 1,875 $14.00 $26,250.00
Disclosure

SEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 09, 2023 Filed Mar 10, 2023 21:05 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 29,971 $29.07 $871,256.97
Disclosure

SEC source: 0000899243-23-007996 · doc4.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.23 to $29.81. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.23 to $29.81. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 21:47 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantStock Option (Right to Buy) · Derivative 108,000 $0.00 Strike: $34.20 $0.00
Disclosure

SEC source: 0000899243-23-004588 · doc4.xml · derivative · entry 1

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires 2033-02-08

F1 · derivative.exercise_date: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 23:04 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 1,872 $0.00 Strike: $14.00 $0.00
Disclosure

SEC source: 0000899243-23-002674 · doc4.xml · derivative · entry 5

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,003

Underlying: Common Stock · 1,872 shares

Expires 2031-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 23:04 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 4,971 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-23-002674 · doc4.xml · derivative · entry 4

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,750

Underlying: Common Stock · 4,971 shares

Expires 2031-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 23:04 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 6,843 $35.66 $244,021.38
Disclosure

SEC source: 0000899243-23-002674 · doc4.xml · nonDerivative · entry 3

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 23:04 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 1,872 $14.00 $26,208.00
Disclosure

SEC source: 0000899243-23-002674 · doc4.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,843

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 23:04 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 4,971 $23.03 $114,482.13
Disclosure

SEC source: 0000899243-23-002674 · doc4.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 21, 2022 Filed Dec 22, 2022 21:42 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 16,326 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-22-039217 · doc4.xml · derivative · entry 6

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,721

Underlying: Common Stock · 16,326 shares

Expires 2031-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
December 21, 2022 Filed Dec 22, 2022 21:42 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 16,326 $29.19 $476,555.94
Disclosure

SEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 4

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 21, 2022 Filed Dec 22, 2022 21:42 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 16,326 $23.03 $375,987.78
Disclosure

SEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 3

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,326

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 20, 2022 Filed Dec 22, 2022 21:42 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 600 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-22-039217 · doc4.xml · derivative · entry 5

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,047

Underlying: Common Stock · 600 shares

Expires 2031-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
December 20, 2022 Filed Dec 22, 2022 21:42 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 600 $28.07 $16,842.00
Disclosure

SEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 20, 2022 Filed Dec 22, 2022 21:42 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 600 $23.03 $13,818.00
Disclosure

SEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 1

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 00:22 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 1,297 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-22-039056 · doc4.xml · derivative · entry 6

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,647

Underlying: Common Stock · 1,297 shares

Expires 2031-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 00:22 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 1,297 $28.44 $36,886.68
Disclosure

SEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 4

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 00:22 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 1,297 $23.03 $29,869.91
Disclosure

SEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 3

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,297

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 15, 2022 Filed Dec 20, 2022 00:22 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 300 $0.00 Strike: $23.03 $0.00
Disclosure

SEC source: 0000899243-22-039056 · doc4.xml · derivative · entry 5

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,944

Underlying: Common Stock · 300 shares

Expires 2031-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Read SEC document
December 15, 2022 Filed Dec 20, 2022 00:22 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 SaleCommon Stock 300 $28.08 $8,424.00
Disclosure

SEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 2

Meisner Lara · CIK 0001883986 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.